<VariationArchive RecordType="classified" VariationID="10492" VariationName="NC_000023.11:g.(?_149478764)_(149505354_?)del" VariationType="Deletion" Accession="VCV000010492" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2014-02-20" MostRecentSubmission="2014-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="25531" VariationID="10492">
      <GeneList>
        <Gene Symbol="IDS" FullName="iduronate 2-sulfatase" GeneID="3423" HGNC_ID="HGNC:5389" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149476988" stop="149505306" display_start="149476988" display_stop="149505306" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="148560294" stop="148586883" display_start="148560294" display_stop="148586883" Strand="-" />
          </Location>
          <OMIM>300823</OMIM>
          <Haploinsufficiency last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=IDS">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-11-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=IDS">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="LOC106050102" FullName="IDS recombination region" GeneID="106050102" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149486745" stop="149503070" display_start="149486745" display_stop="149503070" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC130068781" FullName="ATAC-STARR-seq lymphoblastoid active region 30015" GeneID="130068781" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>Xq28</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="149505051" stop="149505210" display_start="149505051" display_stop="149505210" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NC_000023.11:g.(?_149478764)_(149505354_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq28</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" innerStart="149478764" innerStop="149505354" display_start="149478764" display_stop="149505354" variantLength="26591" Strand="-" />
      </Location>
      <OtherNameList>
        <Name>IDS, DEL</Name>
        <Name>DEL</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.(?_149478764)_(149505354_?)del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.(?_149478764)_(149505354_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="nssv7487150" DB="dbVar" />
        <XRef ID="nsv1197518" DB="dbVar" />
        <XRef Type="Allelic variant" ID="300823.0007" DB="OMIM" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000023.11:g.(?_149478764)_(149505354_?)del AND Mucopolysaccharidosis, MPS-II" Accession="RCV000011238" Version="6">
        <ClassifiedConditionList TraitSetID="2973">
          <ClassifiedCondition DB="MedGen" ID="C0026705">Mucopolysaccharidosis, MPS-II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1992-09-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1992-09-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2014-02-20" MostRecentSubmission="2014-02-20">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1355630</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1906048</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2973" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10834" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hunter Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IDS deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sulfoiduronate sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">SIDS deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 2</ElementValue>
                <XRef ID="MONDO:0010674" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis with skin involvement</ElementValue>
                <XRef ID="MONDO:0019302" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-II</ElementValue>
                <XRef ID="Mucopolysaccharidosis+type+II/4913" DB="Genetic Alliance" />
                <XRef ID="70737009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS (subtype; formerly known as mild MPS II)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Iduronate 2-sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">I2S deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS2</ElementValue>
                <XRef Type="MIM" ID="309900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS II</ElementValue>
                <XRef Type="MIM" ID="309900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6675" />
                <XRef ID="6675" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type II (MPS II; also known as Hunter syndrome) is an X-linked multisystem disorder characterized by glycosaminoglycan (GAG) accumulation. The vast majority of affected individuals are male; on rare occasion heterozygous females manifest findings. Age of onset, disease severity, and rate of progression vary significantly among affected males. In those with early progressive disease, CNS involvement (manifest primarily by progressive cognitive deterioration), progressive airway disease, and cardiac disease usually result in death in the first or second decade of life. In those with slowly progressive disease, the CNS is not (or is minimally) affected, although the effect of GAG accumulation on other organ systems may be early progressive to the same degree as in those who have progressive cognitive decline. Survival into the early adult years with normal intelligence is common in the slowly progressing form of the disease. Additional findings in both forms of MPS II include: short stature; macrocephaly with or without communicating hydrocephalus; macroglossia; hoarse voice; conductive and sensorineural hearing loss; hepatosplenomegaly; dysostosis multiplex; spinal stenosis; and carpal tunnel syndrome.</Attribute>
                <XRef ID="NBK1274" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301451</ID>
                <ID Source="BookShelf">NBK1274</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="PubMed">21863056</ID>
              </Citation>
              <Citation Type="general" Abbrev="Giugliani et al., 2014">
                <ID Source="PubMed">25071396</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/MPS-II.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Iduronate 2-Sulfatase Deficiency, Mucopolysaccharidosis Type II, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/MPS-II-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Mucopolysacchardosis Type II (MPSII): Decreased Iduronate 2-Sulfatase (I2S) activity, 2022</CitationText>
              </Citation>
              <XRef ID="580" DB="Orphanet" />
              <XRef ID="79388" DB="Orphanet" />
              <XRef ID="C0026705" DB="MedGen" />
              <XRef ID="MONDO:0010674" DB="MONDO" />
              <XRef Type="MIM" ID="309900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="31465" SubmissionDate="2014-02-12" DateLastUpdated="2014-02-20" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300823.0007_MUCOPOLYSACCHARIDOSIS, TYPE II" title="IDS, DEL_MUCOPOLYSACCHARIDOSIS, TYPE II" />
        <ClinVarAccession Accession="SCV000031465" DateUpdated="2014-02-20" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1992-09-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In an 8.5-year-old boy with such severe Hunter syndrome (309900) that bladder and bowel control was never achieved, chronic diarrhea was a major problem, and speech was limited and delayed in development, Beck et al. (1992) demonstrated complete lack of the IDS coding sequences and the simultaneous deletion of both DXS466 and DXS304, 2 markers mapped probably not more than 900 kb from the IDS locus. By following the segregation of an RFLP at the IDS locus, Beck et al. (1992) found that the deletion probably occurred in the germ cells of the patient's maternal grandfather. The 2 patients with IDS deletion reported by Wraith et al. (1991) likewise had severe expression of the disease with epileptic seizures and profound mental retardation; they never attained speech. Ptosis was present in 1 of the 2 patients of Wraith et al. (1991) but was not present in the second patient or in the patient reported by Beck et al. (1992) with deletion of IDS. In an addendum, Beck et al. (1992) cited their results suggesting that DXS466 lies within an intron in the 5-prime half of the IDS gene.</Attribute>
              <Citation>
                <ID Source="PubMed">1355630</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">1906048</ID>
              </Citation>
              <XRef DB="OMIM" ID="309900" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDS" />
          </GeneList>
          <Name>IDS, DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300823.0007" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">MUCOPOLYSACCHARIDOSIS, TYPE II</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="31465" TraitType="Disease" MappingType="Name" MappingValue="MUCOPOLYSACCHARIDOSIS, TYPE II" MappingRef="Preferred">
        <MedGen CUI="C0026705" Name="Mucopolysaccharidosis, MPS-II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

